Business ❯ Pharmaceuticals

Vaccine Development

Moderna Novavax Market Impact Research and Development Corporate Governance mRNA Technology Funding AstraZeneca Market Reactions Collaboration Agreements Corporate Communication Market Response Pricing Strategies Market Competition Manufacturing COVID-19 Vaccines Manufacturers Regulatory Affairs Valneva SE Valneva Research Funding COVID-19 Vaccine Technology Transfer Investment Decisions Covid-19 Vaccines Seattle-based Cancer Vaccine Pfizer Moderna Inc. Clinical Trials Corporate Deals Contracts

CEPI Puts Up to $54.3 Million Behind Moderna’s H5 mRNA Bird Flu Vaccine for Phase 3

The multilateral grant replaces canceled U.S. support.

FDA Suspends Valneva’s Ixchiq Chikungunya Vaccine Over Safety Reports

Moderna’s mRNA-1010 Flu Vaccine Outperforms Standard Shot and Advances Toward Approval

FDA Expands Moderna RSV Vaccine to Adults 18–59 at Risk

FDA Approves Moderna’s mNEXSPIKE for Seniors and High-Risk Adults as CDC Drops Recommendations for Healthy Children and Pregnant Women

HHS Withdraws $766 Million From Moderna’s Bird Flu Vaccine Program

Moderna Withdraws Flu-COVID Vaccine Application After FDA Requests More Data

FDA Grants Limited Approval to Novavax’s COVID-19 Vaccine